- $849.87m
- $760.36m
- $14.08m
NASDAQ RESUMED AT 01:58 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:48 PM
NASDAQ RESUMED AT 01:48 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:38 PM
Arbutus Biopharma slips after Europe revokes key patent
Brief: Arbutus Biopharma Corp - EPO Revokes Arbutus Biopharma's European Patent EP 2279254 - SEC Filing
Arbutus Biopharma Q3 revenue and net loss miss analyst estimates
Brief: Arbutus Biopharma Q3 Revenue USD 500 Thousand
Arbutus Biopharma Corp reports results for the quarter ended June 30 - Earnings Summary
Arbutus beats Q2 revenue, net income expectations
Arbutus Biopharma Corp expected to post a loss of 5 cents a share - Earnings Preview
Brief: Arbutus Reacquires Greater China Rights to Imdusiran
Arbutus Biopharma Corp reports results for the quarter ended March 31 - Earnings Summary
Brief: Arbutus Biopharma Q1 Revenue USD 1.8 Million Vs. IBES Estimate USD 1.78 Million
Arbutus Biopharma Corp expected to post a loss of 10 cents a share - Earnings Preview
Analysis: Trump health policy uncertainty sends biotech sector into deeper slump
Arbutus Biopharma Corp reports results for the quarter ended December 31 - Earnings Summary
Arbutus Biopharma Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: Genevant Sciences And Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna